Lapatinib is an oral receptor tyrosine kinase inhibitor which has shown activity in the treatment of metastatic breast cancer. There is no data regarding the side effects of combination of radiotherapy and Lapatinib. 40 female Wistar-albino rats (WAR) were divided into 4 groups; G1 did not receive any treatment, G2 received radiotherapy to whole thoracic region, G3 received Lapatinib without radiotherapy, G4 received Lapatinib with radiotherapy. A total dose of 30 Gy in 10 fractions was given to both lungs. Lapatinib equivalent to 1500 mg/day were calculated according to the mean weight of rats, orally administrated. A comparative analysis was performed by scoring the pulmonary injury between 0 and 3 according to the infiltration of inflammatory cells into the alveolar spaces, alveolar wall thickening and architectural deformation across the entire lung section. In G2 inflammatory cell infiltration, fibrosis with damage to lung structure andformation of small fibrous masses were observed. Alveolar septa were significantly thicker than G1 (p≤ 0.001), which revealed totally normal pulmonary structure. G3 showed minimal alveolar septal thickening and infiltration of inflammatory cells into the alveolar spaces which was not significantly different than G1. Histopathological findings in G4 were similar to those in G2 and statistically different when compared with the G1 and G3 (p≤ 0.001). In this experimental study it has been shown that addition of Lapatinib to radiation did not increase RIPF in rats.
INTRODUCTION
Breast cancer is the most commonly diagnosed cancer among woman in the world. Radiotherapy has a significant role in the treatment of breast cancer as well as other treatment modalities like surgery and systemic treatments.
1,2
Lung is one of the most radiosensitive organ, yet is frequently irradiated as part of treatment for cancers of the breast. In human the early phase of radiation effects in lung becomes apparent at about 1-3 months after radiotherapy, tissue histology shows an increase in type II pneumocytes and a decrease in parenchymal cells and surfactant concentrations. At this phase inflammatory cells are present in the tissues and alveolar macrophages are prominent. Pneumonitis generally subsides after several weeks and is followed by chronic inflammation and fibrosis that develops months or years after irradiation. In this phase, vascular damage and collagen deposition become apparent.
3 Data from animal and human studies indicate that vascular injury and coagulation cascade, cellular adhesion molecules, proinflammatory and profibrotic cytokines and oxidative stress all seem to have vital roles in the development of radiation fibrosis.
4,5
Studies have shown that radiation-induced pulmonary fibrosis (RIPF) is a dynamic process characterized by a constant remodeling of fibrous tissue and long term fibroblast activation.
4-7
The epidermal growth factor receptor family of proteins, including Erb B1/EGFR/Her 1, Erb B2/ Her 2/neu, Erb B3/Her3, and Erb B4/Her 4, have been reported to play a role in tumorigenesis and regulate epithelial cell proliferation, survival and differentiation.
8 Her 2 and EGFR play an important role and positivity in breast cancer cells associated with poor prognosis and unfavorable to therapy. Ongoing clinical trials are investigating the benefits of new targeted therapies, including Erb B and tyrosine kinase inhibitors and antiangiogenesis. These targeted therapies may carry a potential risk for additional pulmonary and cardiac toxicity, in association with radiotherapy.
8,9
Lapatinib, is a small-molecule tyrosine kinase inhibitor that binds reversible to cytoplasmic ATPbinding site in the kinase of EGFR and HER 2, thus inhibiting receptor phosphorylation and activation. 10 In a randomized phase 3 study, lapatinib added to capacitabine improved the time to disease progression compared with capecitabine alone in the metastatic breast cancer.
11 Preclinical data suggest that lapatinib may have a radiosensitizing effect on the metastatic breast cancer cells to the brain which may lead increased side effects when combined in the clinical setting. 12, 13 There is not enough data regarding the late effects of lapatinib when used with RT. In this experimental study we evaluated if concurrent or sequential administration of lapatinib has any impact for the development of radiation induced pulmonary fibrosis (RIPF) in rats. Lung is chosen as it is one of the most radiosensitive organ. Five animals were housed per cage and maintained under identical conditions with food and water provided ad libitum. All experiments were carried out in compliance with the regulations of the institution and the 3R (reduction, replacement, refinement) ethical guidelines. Wistar albino rats were randomized into 4 experimental groups. The first group of rats (Group 1), did not receive any treatment. The second group of animals (Group 2) had irradiation to whole thoracic region. The third group of animals (Group 3) had lapatinib without thoracic irradiation. The fourth group of animals 
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All rats in each group were irradiated to whole thoracic region with Cobalt 60 unit at Radiation Oncology Department. Whole lungs of the rats were simulated and marked prior to irradiation. Animals were anesthetized with an intramuscular (IM) injection of Ketamine-HCL at a dose of 50 mg/kg, prior to simulation and irradiation. Animals were held securely on a foam holder at supine position and plastic bandages were used to immobilize the thoracic region during irradiation (Figure 1-2) . A total dose of 30 Gy in 10 fractions was given to both lungs with an anterior field at 2 cm depth.
Lapatinib equivalent to 1500 mg/day, 60 kg adult dose, were calculated according to the mean weight of rats, orally administrated with a feeding tube twice daily including the weekends until the WAR were sacrificed. The animals were anesthetized and sacrificed with cervical dislocation, 12 weeks after the completion of irradiation.
Histological analysis was carried out on wholelung, paraffin sections (5 µm thick) that were stained with hematoxylin-eosin and Masson's trichrome. Lung sections were assessed and grade of fibrosis was scored for each section according to a scoring system modified from Ashcroft et al. andDowning et al. 14, 15 A semi-quantitative comparative analysis was performed among 4 groups by scoring the pulmonary injury between 0 and 4 according to the infiltration of inflammatory cells into the alveolar spaces, alveolar wall thickening and architectural deformation across the entire lung section. Each criterion had a possible score of 0 to 4, where 0 no injury; 1 minimal injury, 2 mild injury, 3 moderate injury, and 4 marked injury. The total lung injury score was calculated by summing the scores of these three parameters. Slides were then examined and photographed by two independent histologists in blinded fashion under light microscope (BX61, Olympus, Japan) attached with a digital camera (DP72, Olympus, Japan)( Table 2 ). Data obtained from histological scoring were normally distributed as determined by the Kolmogorov-Smirnov test and, therefore, were analyzed with one-way ANOVA followed by post hoc Holm-Sidak testing. Statistical calculations were performed using Sigma Stat for Windows, version 3.0 (Jandel Scientific, San Rafael, CA); (p< 0.001) was considered to be significant.
RESULTS
Pulmonary Histopathology
Control group (G1) demonstrated normal pulmonary architecture with thin alveolar septa and distinct respiratory bronchioles, alveolar sacs, and alveoli ( Figure 3 ; A and B) (Graph 1). On the other hand microscopically findings in the lung speci- 
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International Journal of Hematology and Oncology mens displayed severe lung injury in group 2 inflammatory cell infiltration and increased amount of collagen fibrils in the interstitial area which eventually leaded to thickening of the interalveolar septa and shrinkage of the size of the alveoli. Most of the alveoli were collapsed, and some of the alveoli and alveolar sacs showed compensatory dilatation. Alveolar septa were significantly thicker than the control group (G1) (p< 0.001). (Figure 3 ; C and D) (Graph 1). Small focal fibrous masses were observed in some areas of the lungs in this group. Radiotherapy damaged the lung architecture.
The group which lapatinib treatment is given alone (G3) showed minimal infiltration of inflammatory cells and alveolar septal thickening which were negligible, since there were no statistically significant difference when the scores of the group were compared with those of the control group ( Figure  3 ; E and F) (Graph 1).
The histopathological findings in the group which lapatinib treatment was given together with radiotherapy (G4) was similar to those in G2. Thus, lapatinib when administered concurrently with radiotherapy, did not further augment fibrosis in the lungs and did not impaired the lung damage. Further, similar to the animals in the radiotherapy group, animals in the radiotherapy + lapatinib group had significantly higher total lung injury scores than those in the control (G1) and lapatinib (G3) groups (p< 0.001) (Figure 3 ; G and H) (Graph 1).
DISCUSSION
Breast cancer, is usually associated with an increase of activation of EGFR tyrosine kinases. Lapatinib is an oral tyrosine kinase inhibitor (TKI) that acts intracellulary directly targeting the tyrosine kinase domain of both ErbB-1 and ErbB2 receptors.
A preclinical study 16 , mice bearing xenografts of EGFR + and HER2 + breast cancer cells were treated with lapatinib and fractionated radiotherapy suggested that lapatinib combined with fractionated radiotherapy might be useful against EGFR+ and HER2+ breast cancers by inhibition of downstream signalling ERK1/2 and AKT correlates with sensitization in EGFR + and HER2 + cells. Although lapatinib sensitise breast cancer cells to radiation, we can not obtain any information regarding the toxicity.
A phase I study (EGF10004) 17 , L was administered in 67 patients pretreated with ERB1or HER2 overexpressing metastatic cancer. L was given at doses ranging from 500-1600mg once daily. The most frequent adverse events were diarrhea (42%) and skin rash (31%). The EGF10003
18 study with a daily dosage range of 500-900 mg bid had a similar result as a grade 1-2 gastrointestinal events and rash. In Japan phase I study 19 was designed at doses of 900-1800 mg and the maximum tolerated dose was 1.800 mg daily, 2 patients had grade 2 diarrhea and 1 had grade 1 GGT elevation. These phase I studies recommended that the optimum dose of lapatinib was 1.500 mg daily. Perez et al. 20 analyzed the cardiac function data of 2,812 patients treated with lapatinib, the incidence of left ventricular ejection fraction decrease was 1.3% and were rarely symptomatic and generally reversible.
TKI's are small molecules pass the cell membrane and inhibit several intracellular tyrosine kinases and several growth factor receptors. Up to now there hasn't been approved TKI for the simultaneous use with radiotherapy. All combined toxicity are limited to case reports or studies with small International Journal of Hematology and Oncology numbers of patients. There are limited studies using lapatinib in combination with radiotherapy. Harrington et al. 21 studied about lapatinib in combination with chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck patients. Thirty-one patients were enrolled onto escalating lapatinib dose (500,1000 and 1500 mg/day) and received the same dose of lapatinib plus radiotherapy 66 and 70 Gy and cisplatin 100 mg/m 2 on days 1,22 and 43. The most common grade 3 to 4 adverse events were radiation mucositis, radiation dermatitis, lymphopenia and neutropenia. There was no drug-related cardiotoxicity and interstistial pneumonitis were reported. Adding lapatinib to cisplatin-based chemoradiotherapy did not aggravate cisplatin-induced nausea or vomiting and lapatinib did not enhance radiation mucositis with grade 3 or higher in seen in 35% of patients. Although there is information regarding the combination of radiotherapy with lapatinib in head and neck cancer patients. No data exists regarding the combination of lapatinib with radiotherapy in breast cancer patients Bese et al. 22 also did not show any increased effect of HER2 monoclonal antibody trastuzumab on radiation induced lung fibrosis when combined with radiotherapy .
Targeted drugs are promising therapeutic candidates with a comparatively low toxicity profile. The risk of parallel use of both radiotherapy has not usually been studied.. In this experimental study , it was found that concomitant addition of lapatinib to thoracic radiation did not increase radiation induced pulmonary fibrosis in rats. Further work is needed to prioritize biomarkers for disease-directed studies, and underscores the need for improved trial design strategies in concomitant use of lapatinib with radiotherapy in breast cancer.
Summary
The lung is one of the most radiosensitive organ, yet is frequently irradiated as part of treatment for cancers of the breast. Lapatinib is a small-molecule tyrosine kinase inhibitor. There are limited studies using lapatinib in combination with radiotherapy. In this experimental study we found that concomitant addition of lapatinib to thoracic RT did not increase radiation induced pulmonary fibrosis in rats.
